Company News: Gilead Sciences, Cubist Pharmaceuticals and Calixa Therapeutics

Share this article:
Gilead Sciences said that it will likely end development of darusentan, a once promising endothelin receptor antagonist for treating resistant hypertension, because the agent did not achieve its co-primary endpoints in a phase III trial.

Cubist Pharmaceuticals said it plans to acquire privately held Calixa Therapeutics for $92.5 million in cash and up to $310 million in milestone payments. In the deal, expected to close by year's end, Cubist would obtain Calixa's rights to develop and commercialize the firm's Phase 2 antibiotic CXA-201, which is intended to treat common, serious Gram-negative infections.
Share this article:

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.